CAJ | 학술논문

原发性肝癌作为我国恶性肿瘤病死率仅次于肺癌的疾病,已严重威胁着人民大众的生命健康,并且大多数患者在就医时已处于肿瘤晚期,因此早已失去了一期手术切除的机会,而且肝癌对放化疗的敏感性均较差.经导管肝动脉化疗栓塞术作为不能行手术切除的原发性肝癌的主要治疗方法,虽然其临床效果十分明显,但也有不足之处,肿瘤坏死、清除不彻底,存在残留子灶的可能,术后免疫功能会受到损伤.重组人腺病毒p53可有效感染肿瘤细胞,转录、表达p53蛋白,直接或者通过调节相关基因的表达间接抑制肿瘤细胞生长、诱导细胞凋亡.肝动脉化疗栓塞联合重组人腺病毒p53(rAd-p53)治疗原发性肝癌也越来越受到关注,本文通过总结近几年这方面的研究进展作一简述,以评价其临床应用价值与发展前景.
원발성간암작위아국악성종류병사솔부차우폐암적질병,이엄중위협착인민대음적생명건강,병차대다수환자재취의시이처우종류만기,인차조이실거료일기수술절제적궤회,이차간암대방화료적민감성균교차.경도관간동맥화료전새술작위불능행수술절제적원발성간암적주요치료방법,수연기림상효과십분명현,단야유불족지처,종류배사、청제불철저,존재잔류자조적가능,술후면역공능회수도손상.중조인선병독p53가유효감염종류세포,전록、표체p53단백,직접혹자통과조절상관기인적표체간접억제종류세포생장、유도세포조망.간동맥화료전새연합중조인선병독p53(rAd-p53)치료원발성간암야월래월수도관주,본문통과총결근궤년저방면적연구진전작일간술,이평개기림상응용개치여발전전경.
About the malignant tumor in China,the hepatocellular carcinoma mortality is second only to lung cancer and serious threat to the life and health of the masses.Furthermore,because most patients has been in advanced cancer during medical treatment,so had lost the chance of one-stage surgical resection.However,the sensitivity of hepatocellular carcinoma to chemotherapy,radiotherapy and other treatments are poor.Transcatheter arterial chemoembolization is the main method of the treatment for patients those have lost the chance of operation,though the clinical effect is significant,the inadequate is also presence,such as tumor necrosis,incompletely clear,residual tumor nidus and the damage of the immune function after operation.Recombinant adenovirus p53 gene can validly infect tumor cells,transcription and expression of p53 protein,it also regulate the expression of related genes inhibiting tumor cell growth and induce cell apoptosis directly or indirectly.It is increasingly highly attention that recombincanting rAd-p53 with transcatheter arterial chemoembolization(TACE) to treat hepatocellular carcinoma.In order to evaluate the clinical value and promising future,we will make a brief summary for the research progress in this area in recent years.